日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Upfront Daratumumab With Lenalidomide and Dexamethasone for POEMS Syndrome

达雷妥尤单抗联合来那度胺和地塞米松一线治疗POEMS综合征

期刊:Hemasphere
影响因子:14.6
doi:10.1097/HS9.0000000000000381
Gavriatopoulou, Maria; Ntanasis-Stathopoulos, Ioannis; Fotiou, Despina; Migkou, Magdalini; Eleutherakis-Papaiakovou, Evangelos; Kanellias, Nikolaos; Roussou, Maria; Dialoupi, Ioanna; Malandrakis, Panagiotis; Theodorakakou, Foteini; Kastritis, Efstathios; Terpos, Evangelos; Dimopoulos, Meletios-Athanasios
多发性硬化症
发表日期：2020
文献求助 收藏

Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma

在自体干细胞移植（ASCT）后，采用卡非佐米、来那度胺和地塞米松（KRd）方案进行巩固治疗，可使新诊断的多发性骨髓瘤患者的微小残留病灶（MRD）阴性率显著升高，并在不使用双膦酸盐的情况下改善骨代谢。

期刊:Blood Cancer Journal
影响因子:11.6
doi:10.1038/s41408-020-0297-2
Gavriatopoulou, Maria; Terpos, Evangelos; Ntanasis-Stathopoulos, Ioannis; Malandrakis, Panagiotis; Eleutherakis-Papaiakovou, Evangelos; Papatheodorou, Athanasios; Kanellias, Nikolaos; Migkou, Magdalini; Fotiou, Despina; Dialoupi, Ioanna; Roussou, Maria; Kokkali, Nikoletta-Aikaterini; Kastritis, Efstathios; Dimopoulos, Meletios A
发育与干细胞
干细胞
多发性骨髓瘤
代谢
ASC
骨髓瘤
细胞生物学
发表日期：2020
文献求助 收藏

Carfilzomib-associated renal toxicity is common and unpredictable: a comprehensive analysis of 114 multiple myeloma patients

卡非佐米相关肾毒性常见且难以预测：一项对 114 例多发性骨髓瘤患者的综合分析

期刊:Blood Cancer Journal
影响因子:11.6
doi:10.1038/s41408-020-00381-4
Fotiou, Despina; Roussou, Maria; Gakiopoulou, Charikleia; Psimenou, Erasmia; Gavriatopoulou, Maria; Migkou, Magdalini; Kanellias, Nikolaos; Dialoupi, Ioanna; Eleutherakis-Papaiakovou, Evangelos; Giannouli, Stavroula; Delavinia, Christina; Efstathiou, Kostantinos; Kontogiannis, Sofoklis; Terpos, Evangelos; Dimopoulos, Meletios A; Kastritis, Efstathios
多发性骨髓瘤
毒理研究
骨髓瘤
发表日期：2020
文献求助 收藏

Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone

硼替佐米、来那度胺和地塞米松是治疗轻链淀粉样变性的首选方案。

期刊:Blood Advances
影响因子:7.1
doi:10.1182/bloodadvances.2019000147
Kastritis, Efstathios; Dialoupi, Ioanna; Gavriatopoulou, Maria; Roussou, Maria; Kanellias, Nikolaos; Fotiou, Despina; Ntanasis-Stathopoulos, Ioannis; Papadopoulou, Elektra; Ziogas, Dimitrios C; Stamatelopoulos, Kimon; Manios, Efstathios; Ntalianis, Argyrios; Eleutherakis-Papaiakovou, Evangelos; Papanikolaou, Asimina; Migkou, Magdalini; Papanota, Aristea-Maria; Gakiopoulou, Harikleia; Psimenou, Erasmia; Tselegkidi, Maria Irini; Tsitsilonis, Ourania; Kostopoulos, Ioannis; Terpos, Evangelos; Dimopoulos, Meletios A
发表日期：2019
文献求助 收藏

Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone

来那度胺末次给药剂量、疗程和免疫调节剂（IMiD）停药间隔对接受泊马度胺/地塞米松治疗的多发性骨髓瘤患者的影响

期刊:Blood Advances
影响因子:7.1
doi:10.1182/bloodadvances.2019000539
Kastritis, Efstathios; Roussou, Maria; Gavriatopoulou, Maria; Kanellias, Nikolaos; Migkou, Magdalini; Eleutherakis-Papaiakovou, Evangelos; Ziogas, Dimitrios C; Fotiou, Despina; Ntanasis-Stathopoulos, Ioannis; Dialoupi, Ioanna; Giannouli, Stavroula; Tsirigotis, Panagiotis; Delimpasi, Sossana; Mparmparousi, Despina; Spyropoulou-Vlachou, Mairylin; Xirokosta, Aikaterini; Terpos, Evangelos; Dimopoulos, Meletios A
骨髓瘤
免疫/内分泌
多发性骨髓瘤
发表日期：2019
文献求助 收藏

Colon Adenoma Implicating Myasthenia Gravis: A Case Report of a Patient with Postcolectomy Complications

结肠腺瘤并发重症肌无力：一例结肠切除术后并发症患者的病例报告

期刊:Case Reports in Neurological Medicine
影响因子:0.9
doi:10.1155/2016/6297656
Papachatzakis, Y; Tseliou, E; Tatouli, I; Dialoupi, I; Michas, F; Papadopoulou, E; Kousouris, D; Kontogiannis, S; Dimopoulos, M A
重症肌无力
免疫/内分泌
发表日期：2016
文献求助 收藏